David W. Boyer - 12 Feb 2026 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role
Chief Corp. Affairs Officer
Signature
/s/ Darin Lippoldt, Attorney-in-Fact
Issuer symbol
NBIX
Transactions as of
12 Feb 2026
Net transactions value
-$998,533
Form type
4
Filing time
17 Feb 2026, 17:48:50 UTC
Previous filing
03 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Boyer David W. Chief Corp. Affairs Officer 6027 EDGEWOOD BEND CT., SAN DIEGO /s/ Darin Lippoldt, Attorney-in-Fact 17 Feb 2026 0001909817

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBIX Common Stock Options Exercise $0 +1,600 +34% $0.000000 6,313 12 Feb 2026 Direct
transaction NBIX Common Stock Tax liability $106,358 -864 -14% $123.10 5,449 12 Feb 2026 Direct F1
transaction NBIX Common Stock Options Exercise $0 +1,541 +28% $0.000000 6,990 13 Feb 2026 Direct
transaction NBIX Common Stock Tax liability $103,268 -832 -12% $124.12 6,158 13 Feb 2026 Direct F1
transaction NBIX Common Stock Options Exercise $0 +1,811 +29% $0.000000 7,969 13 Feb 2026 Direct
transaction NBIX Common Stock Tax liability $121,389 -978 -12% $124.12 6,991 13 Feb 2026 Direct F1
transaction NBIX Common Stock Award $0 +9,968 +143% $0.000000 16,959 13 Feb 2026 Direct F2
transaction NBIX Common Stock Tax liability $667,517 -5,378 -32% $124.12 11,581 13 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NBIX Restricted Stock Unit Options Exercise $0 -1,600 -25% $0.000000 4,801 12 Feb 2026 Common Stock 1,600 Direct F3, F4
transaction NBIX Restricted Stock Unit Options Exercise $0 -1,541 -33% $0.000000 3,083 13 Feb 2026 Common Stock 1,541 Direct F3, F5
transaction NBIX Restricted Stock Unit Options Exercise $0 -1,811 -50% $0.000000 1,812 13 Feb 2026 Common Stock 1,811 Direct F3, F6
transaction NBIX Stock Option Award $0 +31,234 $0.000000 31,234 13 Feb 2026 Common Stock 31,234 $124.12 Direct F7
transaction NBIX Restricted Stock Unit Award $0 +5,479 $0.000000 5,479 13 Feb 2026 Common Stock 5,479 Direct F3, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.
F2 On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award.
F3 Each RSU represents a contingent right to receive one share of the Issuer's common stock .
F4 This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 1,600 shares on February 12, 2026, and will vest as to 1,600 shares on February 12, 2027, 1,600 shares on February 12, 2028, and 1,601 shares on February 12, 2029, subject to the terms and conditions of the award.
F5 This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,541 shares on February 13, 2025, vested as to 1,541 shares on February 13, 2026, and will vest as to 1,541 shares on February 13, 2027, and 1,542 shares on February 13, 2028, subject to the terms and conditions of the award.
F6 This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 1,811 shares on February 13, 2024, vested as to 1,811 shares on February 13, 2025, vested as to 1,811 shares on February 13, 2026, and will vest as to 1,812 shares on February 13, 2027, subject to the terms and conditions of the award.
F7 Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
F8 The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030.